In a case that could shake the foundation of the pharmaceutical and biotech industries, New Delhi-based generic drugmaker Ranbaxy Laboratories Limited claims that the main patent for Lipitor -- Pfizer's biggest-selling product and the world's most lucrative drug -- does not cover the form of a key ingredient used in the cholesterol-fighting drug. The suit also spotlights Ranbaxy's Jay Deshmukh, a patent attorney who now finds himself playing David to Pfizer's Goliath.
Font Size: 
Giant Slayer
Corporate Counsel
December 30, 2004
This article requires premium access
This article requires premium access to Law.com. Please sign in or subscribe to read the full text.
